BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONESUPPORT’s Chief Medical Officer, has been appointed to assume a broader role as Head of R&D, Medical and Clinical Affairs.
Emil Billbäck, CEO of BONESUPPORT, commented: “We are pleased to announce the expansion of Michael’s role to head of R&D, Medical and Clinical Affairs, where his experience at BONESUPPORT, both as CMO and prior to this as an independent clinical advisor, as well as his clinical experience as an orthopedic surgeon specialising in trauma care and bone infections, will continue to be extremely valuable.
"We remain focused on progressing FORTIFY to allow for a planned CERAMENT G PMA submission in the US in 2020, generating clinical data in our key target indications, as well as broadening our product offering through new CERAMENT formulations. Longer term we are looking to add innovative products with potential to be market disruptive, selected from our innovative pipeline.”
Diefenbeck founded Scientific Consulting in Orthopaedic Surgery in 2014 and has worked for BoneSupport on a range of clinical projects related to Cerament as an independent clinical advisor.
Diefenbeck studied medicine at Munich and was trained as an orthopaedic surgeon, specialising in trauma care and bone infections. He has 14 years’ clinical experience at different German hospitals. At University Hospital Jena, he finished his PhD in 2011 and has since been involved in surgical education and training programmes for students. He is author of 24 Pub-med listed research articles.
Jerry Chang, Executive Vice President of R&D, is leaving the Company and will transfer to a role as independent consultant, where he will be supporting BONESUPPORT in certain projects.
